8-K: Avidity Biosciences Secures FDA Accelerated Approval Pathway for FSHD Drug Del-Brax, Reports Positive Phase 1/2 Data and Initiates Global Phase 3 Study

Avidity Biosciences announced that the FDA has opened an accelerated approval pathway for delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD), alongside positive topline data from its Phase 1/2 FORTITUDE trial and the initiation of its global confirmatory Phase 3 FORWARD study.

Summary

• The U.S. Food and Drug Administration (FDA) has confirmed an accelerated approval pathway is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD).
• Avidity Biosciences has initiated its global, confirmatory Phase 3 FORWARD study for del-brax, designed to support a full approval package for FSHD patients worldwide.
• The FORWARD study is a randomized, placebo-controlled, double-blind, 18-month trial evaluating 2mg/kg of del-brax every six weeks in approximately 200 people (ages 16-70) with FSHD across about 45 global sites.
• Positive topline data from the dose escalation cohorts of the Phase 1/2 FORTITUDE clinical trial of del-brax in FSHD were announced, involving 39 participants on either 2 mg/kg or 4 mg/kg of del-brax versus placebo over 12 months.
• Del-brax treated participants demonstrated consistent improvement in functional mobility (10-Meter Walk-Run Test and Timed Up and Go) and muscle strength (quantitative muscle testing) compared to placebo.
• Improvements in multiple measures of quality of life, as measured by patient-reported outcomes, were also observed compared to placebo.
• Rapid and significant reductions were seen in levels of KHDC1L (cDUX), a novel DUX4-regulated circulating biomarker, and creatine kinase, a biomarker of muscle damage.
• The drug exhibited favorable long-term safety and tolerability, with most adverse events (AEs) being mild or moderate, no related serious or severe AEs, and no discontinuations.
• The company anticipates submitting a Biologics License Application (BLA) for accelerated approval of del-brax to the FDA in the second half of 2026.
• Topline data from the ongoing, fully enrolled del-brax Phase 1/2 FORTITUDE biomarker cohort are anticipated in the second quarter of 2026, with KHDC1L (cDUX) as the primary endpoint.

Sentiment

Score: 9

Explanation: The document conveys highly positive news, including FDA confirmation of an accelerated approval pathway for a lead candidate in a rare disease with no approved therapies, coupled with strong positive topline clinical data and the initiation of a confirmatory Phase 3 study. This significantly de-risks the program and accelerates its path to market, indicating strong progress and potential for future success.

Positives

• FDA confirmed an accelerated approval pathway is open for del-brax in FSHD, potentially expediting market access.
• Initiation of the global, confirmatory Phase 3 FORWARD study demonstrates commitment to full approval and broad patient access.
• Positive topline data from Phase 1/2 FORTITUDE trial showed consistent improvements in functional mobility (10MWRT, TUG) and muscle strength (QMT) compared to placebo, exceeding Minimal Clinically Important Difference (MCID) at both 2mg/kg and 4mg/kg doses.
• Significant and rapid reductions in KHDC1L (cDUX) and creatine kinase, key biomarkers of FSHD and muscle damage, were observed, supporting the drug's mechanism of action.
• Del-brax demonstrated favorable long-term safety and tolerability, with no related severe or serious adverse events and no study discontinuations.
• Improved quality of life measures were reported by patients, indicating a meaningful clinical benefit.
• The selection of 2mg/kg every six weeks as the dose regimen for registrational studies provides clarity for future development.

Risks

• Data and results from the FORTITUDE trial may not be indicative of final results, may not support BLA submission or accelerated approval, or may not be satisfactory to the FDA.
• New analyses of existing data and results may produce different conclusions than established as of the current date.
• Inability to establish that a novel biomarker (KHDC1L/cDUX) may serve as a surrogate endpoint reasonably likely to predict a clinical benefit, which could hinder accelerated approval.
• Even if approved, Avidity may not be able to execute successful product launches.
• Unexpected adverse side effects or inadequate efficacy of del-brax may delay or limit its development, regulatory approval, and/or commercialization.
• Later developments with the FDA and other global regulators could be inconsistent with the feedback received to date.
• Avidity's approach to the discovery and development of product candidates based on its AOC platform is unproven and may not produce any products of commercial value.
• Potential delays in the commencement, enrollment, data readouts, and completion of clinical trials.
• Dependence on third parties in connection with clinical testing and product manufacturing.
• Legislative, judicial, and regulatory developments in the United States and foreign countries could impact the business.
• Avidity could exhaust its available capital resources sooner than it currently expects.

Future Outlook

Avidity Biosciences plans to submit a Biologics License Application (BLA) for accelerated approval of del-brax to the FDA in the second half of 2026, following anticipated topline data from the FORTITUDE biomarker cohort in Q2 2026. The company is also pursuing full, global approval for del-brax through its newly initiated Phase 3 FORWARD study, aiming to profoundly improve the lives of people with FSHD.

Management Comments

• Sarah Boyce, President & CEO: "Poised for three successive BLA submissions in 12 months starting year-end 2025."
• Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center: "What Matters to Patients is to Have Their Disease Under Control. Over 60% of patients express that slowing or stopping the loss of muscle function would be the most meaningful outcome."

Industry Context

Facioscapulohumeral Muscular Dystrophy (FSHD) is a rare, hereditary disorder causing progressive muscle weakness, pain, fatigue, and disability, with no currently approved therapies. Avidity Biosciences' del-brax, if approved, would be the first disease-modifying treatment for FSHD. The FDA's confirmation of an accelerated approval pathway, leveraging a novel circulating biomarker (cDUX/KHDC1L), is a significant development for rare disease drug development, potentially setting a precedent for future therapies in areas of high unmet medical need.

Comparison to Industry Standards

• Del-brax is on track to be the first disease-modifying treatment for people living with FSHD, addressing a significant unmet medical need as there are currently no approved therapies for this condition.
• The observed reductions in DUX4-regulated biomarkers (cDUX/KHDC1L) are described as "unprecedented and consistent," suggesting a potentially superior biological effect compared to any prior investigational approaches for FSHD.
• Functional mobility improvements in del-brax treated participants exceeded the Minimal Clinically Important Difference (MCID) thresholds derived from the ReSolve natural history study, indicating a clinically meaningful benefit for patients.
• The FDA's acceptance of a novel circulating biomarker (cDUX/KHDC1L) as a primary endpoint for accelerated approval is a significant regulatory milestone, potentially streamlining the development and approval process for rare diseases like FSHD, which often lack established surrogate endpoints.

Stakeholder Impact

• Shareholders: Highly positive impact due to significant de-risking of the lead drug candidate, accelerated regulatory pathway, and strong clinical data, which could lead to increased share price and long-term value.
• Patients (FSHD): Extremely positive impact as del-brax has the potential to be the first disease-modifying treatment for FSHD, offering improvements in functional mobility, muscle strength, and quality of life, addressing a critical unmet medical need.
• Employees: Positive impact due to successful program advancement, potential for future commercialization, and the company's strengthened position in the rare disease therapeutic area.

Next Steps

• Anticipate topline data from the FORTITUDE biomarker cohort in Q2 2026.
• Anticipate submitting a Biologics License Application (BLA) for accelerated approval of del-brax to the FDA in H2 2026.
• Continue the global, confirmatory Phase 3 FORWARD study for full approval of del-brax.

Key Dates

Recommendation

Keywords

Avidity Biosciences, Facioscapulohumeral Muscular Dystrophy, FSHD, delpacibart braxlosiran, del-brax, Accelerated Approval, FDA, Clinical Trial, Phase 3, Phase 1/2, FORTITUDE, FORWARD, DUX4, KHDC1L, cDUX, Muscular Dystrophy, Rare Disease, RNA Therapeutics, Biomarker